Amendment: SEC Form SC 13G/A filed by Oric Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Oric Pharmaceuticals Inc.

Recent Analyst Ratings for
$ORIC

$ORIC
Press Releases

$ORIC
Analyst Ratings

$ORIC
Large Ownership Changes

Chat with this insight

Fastest customizable press release news feed in the world

ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Wells Fargo initiated coverage on ORIC Pharmaceuticals with a new price target

Stifel initiated coverage on ORIC Pharmaceuticals with a new price target

Cantor Fitzgerald initiated coverage on ORIC Pharmaceuticals

This live feed shows all institutional transactions in real time.

11/14/24 5:14:58 PM ET

$ORIC

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ORIC alert in real time by email

SC 13G/A 1 d851421dsc13ga.htm SC 13G/A SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

ORIC PHARMACEUTICALS, INC.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

68622P109

(CUSIP Number)

September 30, 2024

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 68622P109				13G

(1)

All such shares are held of record by TCG II LP (as defined in Item 2(a) below). TCG II GP LP (as defined in Item 2(a) below) is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson and David Goeddel are the managing partners of TCG II LP and may each be deemed to share voting, investment and dispositive power with respect to these securities.

(2)	Based on 70,542,476 shares of Common Stock outstanding as of July 31, 2024, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 filed with the Securities and Exchange Commission (the “Commission”) on August 12, 2024 (the “Form 10-Q”).


CUSIP No. 68622P109				13G

(1)

All such shares are held of record by TCG II LP. TCG II GP LP is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson and David Goeddel are the managing partners of TCG II LP and may each be deemed to share voting, investment and dispositive power with respect to these securities.

(2)	Based on 70,542,476 shares of Common Stock outstanding as of July 31, 2024 as reported by the Issuer in its Form 10-Q.


CUSIP No. 68622P109				13G

(1)

3,540,777 of such shares are held of record by TCG II LP. TCG II GP LP is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson and David Goeddel are the managing partners of TCG II LP and may each be deemed to share voting, investment and dispositive power with respect to these securities.

(2)	Based on 70,542,476 shares of Common Stock outstanding as of July 31, 2024 as reported by the Issuer in its Form 10-Q.


CUSIP No. 68622P109				13G

(1)

(2)	Based on 70,542,476 shares of Common Stock outstanding as of July 31, 2024 as reported by the Issuer in its Form 10-Q.


CUSIP No. 68622P109				13G

This Amendment No. 2 (“Amendment No. 2”) amends and supplements the Schedule 13G initially filed with the Commission on February 16, 2021, as amended by Amendment No. 1 filed with the Commission on February 11, 2022 (collectively, the “Original Schedule 13G”) and is being filed by The Column Group II, LP (“TCG II LP”), The Column Group II GP, LP (“TCG II GP LP” and together with TCG II LP, the “Reporting Entities”) and Peter Svennilson (“Svennilson”) and David Goeddel (“Goeddel” and together with Svennilson, the “Managing Individuals”). The Reporting Entities and the Managing Individuals collectively are referred to as the “Reporting Persons”. The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act was filed as Exhibit 1 to the Original Schedule 13G . Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13G remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment No. 2 have the meanings ascribed to them in the Original Schedule 13G.

Item 4.

Ownership.

(a)

Amount beneficially owned:

See Row 9 of the cover page for each Reporting Person and the corresponding footnotes.*

(b)

Percent of class:

See Row 11 of the cover page for each Reporting Person and the corresponding footnotes.*

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote

See Row 5 of the cover page for each Reporting Person and the corresponding footnotes.*

(ii)

Shared power to vote or to direct the vote

See Row 6 of the cover page for each Reporting Person and the corresponding footnotes.*

(iii)

Sole power to dispose or to direct the disposition of

See Row 7 of the cover page for each Reporting Person and the corresponding footnotes.*

(iv)

Shared power to dispose or to direct the disposition of

See Row 8 of the cover page for each Reporting Person and the corresponding footnotes.*

*	Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein.


CUSIP No. 68622P109				13G

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: November 14, 2024


THE COLUMN GROUP II, LP		THE COLUMN GROUP II GP, LP

By:	The Column Group II GP, LP

By:	/s/ James Evangelista, Attorney in Fact	By:	/s/ James Evangelista, Attorney in Fact
Name:	James Evangelista	Name:	James Evangelista
Title:	Attorney in Fact	Title:	Attorney in Fact



By:		/s/ James Evangelista, Attorney in Fact for Peter Svennilson

By:		/s/ James Evangelista, Attorney in Fact for David Goeddel

Get the next $ORIC alert in real time by email

Date	Price Target	Rating	Analyst
10/31/2024	$20.00	Overweight	Wells Fargo
9/6/2024	$20.00	Buy	Stifel
2/23/2024		Overweight	Cantor Fitzgerald
9/22/2023	$8.00	Outperform	Wedbush
3/23/2023	$16.00	Neutral → Buy	H.C. Wainwright
3/21/2023	$15.00	Neutral → Buy	Guggenheim
3/16/2023	$14.00	Perform → Outperform	Oppenheimer
7/18/2022		Perform	Oppenheimer

NAMES OF REPORTING PERSONS

The Column Group II, LP

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

(a) ☐ (b) ☒

SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware